- Home
- HASI vs ACLX Comparison
HASI vs ACLX Comparison
Compare HASI & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HASI
- ACLX
- Stock Information
- Founded
- HASI 1981
- ACLX 2015
- Country
- HASI United States
- ACLX United States
- Employees
- HASI N/A
- ACLX N/A
- Industry
- HASI Real Estate Investment Trusts
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- HASI Real Estate
- ACLX Health Care
- Exchange
- HASI Nasdaq
- ACLX Nasdaq
- Market Cap
- HASI 3.8B
- ACLX 4.4B
- IPO Year
- HASI 2013
- ACLX 2022
- Fundamental
- Price
- HASI $30.53
- ACLX $91.87
- Analyst Decision
- HASI Strong Buy
- ACLX Strong Buy
- Analyst Count
- HASI 6
- ACLX 13
- Target Price
- HASI $38.67
- ACLX $112.69
- AVG Volume (30 Days)
- HASI 1.3M
- ACLX 546.4K
- Earning Date
- HASI 11-06-2025
- ACLX 11-06-2025
- Dividend Yield
- HASI 5.63%
- ACLX N/A
- EPS Growth
- HASI N/A
- ACLX N/A
- EPS
- HASI 1.59
- ACLX N/A
- Revenue
- HASI $92,418,000.00
- ACLX $56,979,000.00
- Revenue This Year
- HASI $184.19
- ACLX N/A
- Revenue Next Year
- HASI $13.31
- ACLX $210.73
- P/E Ratio
- HASI $18.80
- ACLX N/A
- Revenue Growth
- HASI N/A
- ACLX N/A
- 52 Week Low
- HASI $21.98
- ACLX $47.86
- 52 Week High
- HASI $36.56
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- HASI 61.50
- ACLX 74.98
- Support Level
- HASI $29.21
- ACLX $84.60
- Resistance Level
- HASI $31.06
- ACLX $90.41
- Average True Range (ATR)
- HASI 0.73
- ACLX 3.44
- MACD
- HASI -0.12
- ACLX 0.54
- Stochastic Oscillator
- HASI 59.92
- ACLX 85.60
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.